A randomized controlled trial of probiotics to reduce the severity of oral mucositis in patients with oropharyngeal carcinoma undergoing concurrent chemoradiotherapy.
- 2026-01
- RCT · n = 70
- Journal of cancer research and therapeutics 22(1)
- Saloni Sojitra
- Tej Prakash Soni
- Nidhi Patni
- Dinesh Kumar Singh
- Naresh Jakhotia
- Sheh Rawat
- Anil Kumar Gupta
- Tara Chand Gupta
- Naresh Ledwani
- Harish Singhal
- Shantanu Sharma
- Ravindra Singh Gothwal
- PubMed: 41910295
- DOI: 10.4103/jcrt.jcrt_1070_25
- High evidence
- Clinical
Patients in the probiotics arm experienced significantly less grade 3 oral mucositis (four patients, 11.43%) and grade 3 dysphagia (six patients, 17.14%) compared to patients in the control arm (12 patients, 34.29% and 13 patients, 37.14%, respectively; P < 0.001).
- Effect
- Beneficial
- Effect size
- Large
- Significant
- Yes
- Dose
- 6.5 billion CFU/day (65 ml Yakult)